Page last updated: 2024-11-04

terazosin and Parkinsonian Disorders

terazosin has been researched along with Parkinsonian Disorders in 2 studies

Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
"We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs."1.51Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. ( Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C, 2019)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cai, R1
Zhang, Y1
Simmering, JE1
Schultz, JL1
Li, Y1
Fernandez-Carasa, I1
Consiglio, A1
Raya, A1
Polgreen, PM1
Narayanan, NS1
Yuan, Y1
Chen, Z1
Su, W1
Han, Y1
Zhao, C1
Gao, L1
Ji, X1
Welsh, MJ1
Liu, L1
Seppi, K1
Puschban, Z1
Stefanova, N1
Scherfler, C1
Mueller, J1
Poewe, W1
Wenning, GK1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860]Phase 1/Phase 240 participants (Anticipated)Interventional2024-10-31Not yet recruiting
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364]Phase 215 participants (Anticipated)Interventional2022-09-23Recruiting
Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040]Phase 118 participants (Anticipated)Interventional2021-03-26Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

2 other studies available for terazosin and Parkinsonian Disorders

ArticleYear
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
    Nature medicine, 2001, Volume: 7, Issue:2

    Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models,

2001